Composition for treating retinal or macular diseases

JP2025520099A5Pending Publication Date: 2026-05-25NEURACLE GENETICS INC

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: JP · JP
Patent Type: Applications
Current Assignee / Owner: NEURACLE GENETICS INC
Filing Date: 2023-05-31
Publication Date: 2026-05-25

Application Information

Patent Timeline

31 May 2023

Application

25 May 2026

Publication

JP2025520099A5

IPC: A61K38/16; C12N15/864; C12N15/63; C12N5/10; C12N7/01; C12N15/09; A61P27/02; A61P9/10; A61K35/76; A61K48/00; A61K9/14; C12N15/12; C07K14/47

CPC: C07K14/47; A61P27/02; C12N15/86; C07K14/005; C12N2750/14143; C12N2830/42; A61K48/005; A61K38/195

AI Tagging

Application Domain

Senses disorder Powder delivery

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

AI Technical Summary

Technical Problem

Current treatments for retinal and macular diseases, such as diabetic retinopathy and age-related macular degeneration, lack effective therapeutic options that can restore damaged retinal tissues and improve visual function.

Method used

A pharmaceutical composition comprising a polypeptide with at least 70% sequence identity to TAFA proteins, encoded by a nucleic acid, delivered via an adeno-associated virus (AAV) vector, to promote retinal repair and function.

Benefits of technology

The composition effectively restores damaged retinas to normal function, offering potential therapeutic benefits for retinal and macular diseases by promoting cellular repair and visual recovery.

✦ Generated by Eureka AI based on patent content.

Smart Images

Figure 00000000_0000_ABST
Figure 00000000_0001_ABST

Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating a retinal or macular disease, which comprises a polypeptide comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of a TAFA protein (for example, TAFA1 to TAFA4), a nucleic acid encoding the polypeptide, a vector containing the nucleic acid, a recombinant virus particle containing the vector and a capsid protein, or a cell containing the nucleic acid or the vector. The present invention also relates to an adeno-associated virus (AAV) vector containing a nucleic acid encoding a polypeptide comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence of a TAFA protein, and a recombinant virus particle containing the AAV vector and a capsid protein. The AAV vector, recombinant virus or composition containing the same of the present invention can be usefully used for preventing or treating a retinal or macular disease by restoring the damaged retina.

Need to check novelty before this filing date? Find Prior Art